Shun‐ichi Isa

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 263 citations · Full text

Medicine, Oncology, Pharmacology +16

Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR

Masaru Watanabe, Tomoya Kawaguchi, Shun‐ichi Isa et al. · Clinical Cancer Research · 2015 · 224 citations

Medicine, Molecular Biology, Oncology +17

Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study

Tomoya Kawaguchi, Yasuhiro Koh, Masahiko Ando et al. · Journal of Clinical Oncology · 2016 · 126 citations

Medicine, Genetics, Oncology +16

Trialkyltin Compounds Bind Retinoid X Receptor to Alter Human Placental Endocrine Functions

Tsuyoshi Nakanishi, Jun‐ichi Nishikawa, Youhei Hiromori et al. · Molecular Endocrinology · 2005 · 121 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +17

Pretreatment advanced lung cancer inflammation index (<scp>ALI</scp>) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Takayuki Shiroyama, Hidekazu Suzuki, Motohiro Tamiya et al. · Cancer Medicine · 2017 · 121 citations · Full text

Medicine, Oncology, Inflammation +16